Creative Medical Technology (NASDAQ:CELZ) Posts Quarterly Earnings Results, Misses Estimates By $0.31 EPS

Posted by on May 11th, 2025

Creative Medical Technology (NASDAQ:CELZ – Get Free Report) posted its earnings results on Friday. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.31), Zacks reports.

Creative Medical Technology Price Performance

NASDAQ:CELZ opened at $2.15 on Friday. The company has a market cap of $9.43 million, a P/E ratio of -0.57 and a beta of 2.00. The firm’s fifty day moving average price is $2.48 and its two-hundred day moving average price is $2.89. Creative Medical Technology has a one year low of $1.69 and a one year high of $6.90.

About Creative Medical Technology

(Get Free Report)

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.

Featured Stories

Earnings History for Creative Medical Technology (NASDAQ:CELZ)

Receive News & Ratings for Creative Medical Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Creative Medical Technology and related companies with MarketBeat.com's FREE daily email newsletter.